nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—PTGS1—esophageal cancer	0.372	0.636	CbGaD
Etodolac—PTGS2—esophageal cancer	0.213	0.364	CbGaD
Etodolac—PTGS2—Cisplatin—esophageal cancer	0.0623	0.344	CbGbCtD
Etodolac—CYP2C9—Capecitabine—esophageal cancer	0.042	0.232	CbGbCtD
Etodolac—SLC22A6—Methotrexate—esophageal cancer	0.0299	0.165	CbGbCtD
Etodolac—ALB—Methotrexate—esophageal cancer	0.0255	0.141	CbGbCtD
Etodolac—CYP2C9—Cisplatin—esophageal cancer	0.0212	0.117	CbGbCtD
Etodolac—Melaena—Capecitabine—esophageal cancer	0.000555	0.00601	CcSEcCtD
Etodolac—Colitis—Capecitabine—esophageal cancer	0.000546	0.0059	CcSEcCtD
Etodolac—Skin exfoliation—Capecitabine—esophageal cancer	0.000543	0.00587	CcSEcCtD
Etodolac—Irritability—Cisplatin—esophageal cancer	0.000534	0.00578	CcSEcCtD
Etodolac—Oesophagitis—Capecitabine—esophageal cancer	0.000519	0.00562	CcSEcCtD
Etodolac—Urine output increased—Capecitabine—esophageal cancer	0.000514	0.00556	CcSEcCtD
Etodolac—Mouth ulceration—Capecitabine—esophageal cancer	0.000514	0.00556	CcSEcCtD
Etodolac—Ecchymosis—Capecitabine—esophageal cancer	0.000514	0.00556	CcSEcCtD
Etodolac—Sepsis—Capecitabine—esophageal cancer	0.000493	0.00534	CcSEcCtD
Etodolac—Proteinuria—Methotrexate—esophageal cancer	0.000481	0.00521	CcSEcCtD
Etodolac—Protein urine present—Methotrexate—esophageal cancer	0.000475	0.00514	CcSEcCtD
Etodolac—Pancreatitis—Cisplatin—esophageal cancer	0.000474	0.00513	CcSEcCtD
Etodolac—Photosensitivity—Capecitabine—esophageal cancer	0.00047	0.00508	CcSEcCtD
Etodolac—Polyuria—Capecitabine—esophageal cancer	0.00047	0.00508	CcSEcCtD
Etodolac—Abdominal discomfort—Cisplatin—esophageal cancer	0.000464	0.00502	CcSEcCtD
Etodolac—Vascular purpura—Capecitabine—esophageal cancer	0.000461	0.00499	CcSEcCtD
Etodolac—Deafness—Capecitabine—esophageal cancer	0.000461	0.00499	CcSEcCtD
Etodolac—Pancytopenia—Cisplatin—esophageal cancer	0.000459	0.00497	CcSEcCtD
Etodolac—Oliguria—Methotrexate—esophageal cancer	0.000459	0.00497	CcSEcCtD
Etodolac—Glossitis—Methotrexate—esophageal cancer	0.000459	0.00497	CcSEcCtD
Etodolac—Hepatic failure—Capecitabine—esophageal cancer	0.000459	0.00497	CcSEcCtD
Etodolac—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000457	0.00495	CcSEcCtD
Etodolac—Ulcer—Methotrexate—esophageal cancer	0.000447	0.00484	CcSEcCtD
Etodolac—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.000447	0.00484	CcSEcCtD
Etodolac—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000437	0.00473	CcSEcCtD
Etodolac—Thirst—Capecitabine—esophageal cancer	0.000433	0.00469	CcSEcCtD
Etodolac—Renal impairment—Capecitabine—esophageal cancer	0.000433	0.00469	CcSEcCtD
Etodolac—Vasculitis—Methotrexate—esophageal cancer	0.000433	0.00469	CcSEcCtD
Etodolac—Dermatitis bullous—Capecitabine—esophageal cancer	0.000432	0.00467	CcSEcCtD
Etodolac—Purpura—Capecitabine—esophageal cancer	0.000428	0.00463	CcSEcCtD
Etodolac—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000425	0.0046	CcSEcCtD
Etodolac—Renal failure—Cisplatin—esophageal cancer	0.000424	0.00459	CcSEcCtD
Etodolac—Myocardial infarction—Cisplatin—esophageal cancer	0.000423	0.00457	CcSEcCtD
Etodolac—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000421	0.00456	CcSEcCtD
Etodolac—Stomatitis—Cisplatin—esophageal cancer	0.00042	0.00455	CcSEcCtD
Etodolac—Conjunctivitis—Cisplatin—esophageal cancer	0.000419	0.00454	CcSEcCtD
Etodolac—Melaena—Methotrexate—esophageal cancer	0.000413	0.00447	CcSEcCtD
Etodolac—Cystitis noninfective—Methotrexate—esophageal cancer	0.000413	0.00447	CcSEcCtD
Etodolac—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000413	0.00446	CcSEcCtD
Etodolac—Cystitis—Methotrexate—esophageal cancer	0.000409	0.00442	CcSEcCtD
Etodolac—Skin exfoliation—Methotrexate—esophageal cancer	0.000404	0.00437	CcSEcCtD
Etodolac—Aplastic anaemia—Methotrexate—esophageal cancer	0.000397	0.0043	CcSEcCtD
Etodolac—Irritability—Capecitabine—esophageal cancer	0.000394	0.00426	CcSEcCtD
Etodolac—Coma—Methotrexate—esophageal cancer	0.000387	0.00418	CcSEcCtD
Etodolac—Ecchymosis—Methotrexate—esophageal cancer	0.000383	0.00414	CcSEcCtD
Etodolac—Mouth ulceration—Methotrexate—esophageal cancer	0.000383	0.00414	CcSEcCtD
Etodolac—Urine output increased—Methotrexate—esophageal cancer	0.000383	0.00414	CcSEcCtD
Etodolac—Bladder pain—Methotrexate—esophageal cancer	0.000383	0.00414	CcSEcCtD
Etodolac—Abdominal pain upper—Capecitabine—esophageal cancer	0.000377	0.00408	CcSEcCtD
Etodolac—Visual impairment—Cisplatin—esophageal cancer	0.000373	0.00404	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000371	0.00402	CcSEcCtD
Etodolac—Sepsis—Methotrexate—esophageal cancer	0.000367	0.00397	CcSEcCtD
Etodolac—Gastritis—Capecitabine—esophageal cancer	0.000365	0.00395	CcSEcCtD
Etodolac—Tinnitus—Cisplatin—esophageal cancer	0.000361	0.00391	CcSEcCtD
Etodolac—Lymphadenopathy—Methotrexate—esophageal cancer	0.00036	0.0039	CcSEcCtD
Etodolac—Flushing—Cisplatin—esophageal cancer	0.000359	0.00389	CcSEcCtD
Etodolac—Abdominal distension—Capecitabine—esophageal cancer	0.000359	0.00388	CcSEcCtD
Etodolac—Asthma—Capecitabine—esophageal cancer	0.000357	0.00386	CcSEcCtD
Etodolac—Bronchospasm—Capecitabine—esophageal cancer	0.000351	0.0038	CcSEcCtD
Etodolac—Photosensitivity—Methotrexate—esophageal cancer	0.00035	0.00378	CcSEcCtD
Etodolac—Polyuria—Methotrexate—esophageal cancer	0.00035	0.00378	CcSEcCtD
Etodolac—Arrhythmia—Cisplatin—esophageal cancer	0.000346	0.00374	CcSEcCtD
Etodolac—Bronchitis—Capecitabine—esophageal cancer	0.000343	0.00371	CcSEcCtD
Etodolac—Alopecia—Cisplatin—esophageal cancer	0.000342	0.0037	CcSEcCtD
Etodolac—Abdominal discomfort—Capecitabine—esophageal cancer	0.000342	0.0037	CcSEcCtD
Etodolac—Hepatic failure—Methotrexate—esophageal cancer	0.000342	0.0037	CcSEcCtD
Etodolac—Pancytopenia—Capecitabine—esophageal cancer	0.000339	0.00366	CcSEcCtD
Etodolac—Neutropenia—Capecitabine—esophageal cancer	0.000333	0.00361	CcSEcCtD
Etodolac—Dysuria—Capecitabine—esophageal cancer	0.000333	0.00361	CcSEcCtD
Etodolac—Flatulence—Cisplatin—esophageal cancer	0.000332	0.00359	CcSEcCtD
Etodolac—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000325	0.00352	CcSEcCtD
Etodolac—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000325	0.00352	CcSEcCtD
Etodolac—Visual disturbance—Methotrexate—esophageal cancer	0.000324	0.00351	CcSEcCtD
Etodolac—Hyperglycaemia—Capecitabine—esophageal cancer	0.000322	0.00348	CcSEcCtD
Etodolac—Pneumonia—Capecitabine—esophageal cancer	0.00032	0.00346	CcSEcCtD
Etodolac—Vision blurred—Cisplatin—esophageal cancer	0.000318	0.00344	CcSEcCtD
Etodolac—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000317	0.00343	CcSEcCtD
Etodolac—Tremor—Cisplatin—esophageal cancer	0.000316	0.00342	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000315	0.00341	CcSEcCtD
Etodolac—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000313	0.00339	CcSEcCtD
Etodolac—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000313	0.00339	CcSEcCtD
Etodolac—Ill-defined disorder—Cisplatin—esophageal cancer	0.000313	0.00338	CcSEcCtD
Etodolac—Renal failure—Capecitabine—esophageal cancer	0.000313	0.00338	CcSEcCtD
Etodolac—Myocardial infarction—Capecitabine—esophageal cancer	0.000312	0.00337	CcSEcCtD
Etodolac—Anaemia—Cisplatin—esophageal cancer	0.000312	0.00337	CcSEcCtD
Etodolac—Stomatitis—Capecitabine—esophageal cancer	0.00031	0.00335	CcSEcCtD
Etodolac—Jaundice—Capecitabine—esophageal cancer	0.00031	0.00335	CcSEcCtD
Etodolac—Conjunctivitis—Capecitabine—esophageal cancer	0.000309	0.00334	CcSEcCtD
Etodolac—Malaise—Cisplatin—esophageal cancer	0.000304	0.00329	CcSEcCtD
Etodolac—Haematuria—Capecitabine—esophageal cancer	0.000303	0.00328	CcSEcCtD
Etodolac—Leukopenia—Cisplatin—esophageal cancer	0.000302	0.00326	CcSEcCtD
Etodolac—Agranulocytosis—Capecitabine—esophageal cancer	0.000297	0.00321	CcSEcCtD
Etodolac—Irritability—Methotrexate—esophageal cancer	0.000293	0.00317	CcSEcCtD
Etodolac—Convulsion—Cisplatin—esophageal cancer	0.000292	0.00316	CcSEcCtD
Etodolac—Myalgia—Cisplatin—esophageal cancer	0.000287	0.00311	CcSEcCtD
Etodolac—Haemoglobin—Capecitabine—esophageal cancer	0.000287	0.0031	CcSEcCtD
Etodolac—Rhinitis—Capecitabine—esophageal cancer	0.000286	0.0031	CcSEcCtD
Etodolac—Anxiety—Cisplatin—esophageal cancer	0.000286	0.00309	CcSEcCtD
Etodolac—Hepatitis—Capecitabine—esophageal cancer	0.000285	0.00309	CcSEcCtD
Etodolac—Haemorrhage—Capecitabine—esophageal cancer	0.000285	0.00309	CcSEcCtD
Etodolac—Discomfort—Cisplatin—esophageal cancer	0.000283	0.00307	CcSEcCtD
Etodolac—Pharyngitis—Capecitabine—esophageal cancer	0.000283	0.00307	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000277	0.00299	CcSEcCtD
Etodolac—Anaphylactic shock—Cisplatin—esophageal cancer	0.000275	0.00298	CcSEcCtD
Etodolac—Oedema—Cisplatin—esophageal cancer	0.000275	0.00298	CcSEcCtD
Etodolac—Visual impairment—Capecitabine—esophageal cancer	0.000275	0.00298	CcSEcCtD
Etodolac—Infection—Cisplatin—esophageal cancer	0.000273	0.00296	CcSEcCtD
Etodolac—Erythema multiforme—Capecitabine—esophageal cancer	0.00027	0.00292	CcSEcCtD
Etodolac—Thrombocytopenia—Cisplatin—esophageal cancer	0.000269	0.00291	CcSEcCtD
Etodolac—Tachycardia—Cisplatin—esophageal cancer	0.000268	0.00291	CcSEcCtD
Etodolac—Tinnitus—Capecitabine—esophageal cancer	0.000266	0.00288	CcSEcCtD
Etodolac—Hyperhidrosis—Cisplatin—esophageal cancer	0.000266	0.00288	CcSEcCtD
Etodolac—Asthma—Methotrexate—esophageal cancer	0.000265	0.00287	CcSEcCtD
Etodolac—Flushing—Capecitabine—esophageal cancer	0.000265	0.00287	CcSEcCtD
Etodolac—Eosinophilia—Methotrexate—esophageal cancer	0.000263	0.00284	CcSEcCtD
Etodolac—Anorexia—Cisplatin—esophageal cancer	0.000262	0.00284	CcSEcCtD
Etodolac—Pancreatitis—Methotrexate—esophageal cancer	0.00026	0.00282	CcSEcCtD
Etodolac—Hypotension—Cisplatin—esophageal cancer	0.000257	0.00278	CcSEcCtD
Etodolac—Chills—Capecitabine—esophageal cancer	0.000256	0.00277	CcSEcCtD
Etodolac—Arrhythmia—Capecitabine—esophageal cancer	0.000255	0.00276	CcSEcCtD
Etodolac—Abdominal discomfort—Methotrexate—esophageal cancer	0.000254	0.00275	CcSEcCtD
Etodolac—Alopecia—Capecitabine—esophageal cancer	0.000252	0.00273	CcSEcCtD
Etodolac—Pancytopenia—Methotrexate—esophageal cancer	0.000252	0.00273	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000251	0.00271	CcSEcCtD
Etodolac—Dysuria—Methotrexate—esophageal cancer	0.000248	0.00269	CcSEcCtD
Etodolac—Neutropenia—Methotrexate—esophageal cancer	0.000248	0.00269	CcSEcCtD
Etodolac—Paraesthesia—Cisplatin—esophageal cancer	0.000247	0.00267	CcSEcCtD
Etodolac—Dyspnoea—Cisplatin—esophageal cancer	0.000245	0.00265	CcSEcCtD
Etodolac—Flatulence—Capecitabine—esophageal cancer	0.000245	0.00265	CcSEcCtD
Etodolac—Dysgeusia—Capecitabine—esophageal cancer	0.000243	0.00263	CcSEcCtD
Etodolac—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000242	0.00262	CcSEcCtD
Etodolac—Decreased appetite—Cisplatin—esophageal cancer	0.000239	0.00259	CcSEcCtD
Etodolac—Pneumonia—Methotrexate—esophageal cancer	0.000238	0.00258	CcSEcCtD
Etodolac—Pain—Cisplatin—esophageal cancer	0.000235	0.00255	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000235	0.00254	CcSEcCtD
Etodolac—Vision blurred—Capecitabine—esophageal cancer	0.000234	0.00253	CcSEcCtD
Etodolac—Tremor—Capecitabine—esophageal cancer	0.000233	0.00252	CcSEcCtD
Etodolac—Renal failure—Methotrexate—esophageal cancer	0.000233	0.00252	CcSEcCtD
Etodolac—Stomatitis—Methotrexate—esophageal cancer	0.000231	0.0025	CcSEcCtD
Etodolac—Ill-defined disorder—Capecitabine—esophageal cancer	0.000231	0.00249	CcSEcCtD
Etodolac—Conjunctivitis—Methotrexate—esophageal cancer	0.00023	0.00249	CcSEcCtD
Etodolac—Anaemia—Capecitabine—esophageal cancer	0.00023	0.00248	CcSEcCtD
Etodolac—Sweating—Methotrexate—esophageal cancer	0.000227	0.00246	CcSEcCtD
Etodolac—Feeling abnormal—Cisplatin—esophageal cancer	0.000227	0.00245	CcSEcCtD
Etodolac—Haematuria—Methotrexate—esophageal cancer	0.000226	0.00244	CcSEcCtD
Etodolac—Malaise—Capecitabine—esophageal cancer	0.000224	0.00242	CcSEcCtD
Etodolac—Vertigo—Capecitabine—esophageal cancer	0.000223	0.00242	CcSEcCtD
Etodolac—Syncope—Capecitabine—esophageal cancer	0.000223	0.00241	CcSEcCtD
Etodolac—Leukopenia—Capecitabine—esophageal cancer	0.000222	0.00241	CcSEcCtD
Etodolac—Agranulocytosis—Methotrexate—esophageal cancer	0.000221	0.00239	CcSEcCtD
Etodolac—Palpitations—Capecitabine—esophageal cancer	0.00022	0.00238	CcSEcCtD
Etodolac—Loss of consciousness—Capecitabine—esophageal cancer	0.000218	0.00236	CcSEcCtD
Etodolac—Body temperature increased—Cisplatin—esophageal cancer	0.000217	0.00235	CcSEcCtD
Etodolac—Hypertension—Capecitabine—esophageal cancer	0.000214	0.00232	CcSEcCtD
Etodolac—Haemoglobin—Methotrexate—esophageal cancer	0.000214	0.00231	CcSEcCtD
Etodolac—Haemorrhage—Methotrexate—esophageal cancer	0.000212	0.0023	CcSEcCtD
Etodolac—Hepatitis—Methotrexate—esophageal cancer	0.000212	0.0023	CcSEcCtD
Etodolac—Myalgia—Capecitabine—esophageal cancer	0.000212	0.00229	CcSEcCtD
Etodolac—Arthralgia—Capecitabine—esophageal cancer	0.000212	0.00229	CcSEcCtD
Etodolac—Pharyngitis—Methotrexate—esophageal cancer	0.000211	0.00228	CcSEcCtD
Etodolac—Anxiety—Capecitabine—esophageal cancer	0.000211	0.00228	CcSEcCtD
Etodolac—Discomfort—Capecitabine—esophageal cancer	0.000209	0.00226	CcSEcCtD
Etodolac—Dry mouth—Capecitabine—esophageal cancer	0.000207	0.00224	CcSEcCtD
Etodolac—Visual impairment—Methotrexate—esophageal cancer	0.000205	0.00222	CcSEcCtD
Etodolac—Confusional state—Capecitabine—esophageal cancer	0.000204	0.00221	CcSEcCtD
Etodolac—Oedema—Capecitabine—esophageal cancer	0.000203	0.00219	CcSEcCtD
Etodolac—Hypersensitivity—Cisplatin—esophageal cancer	0.000203	0.00219	CcSEcCtD
Etodolac—Infection—Capecitabine—esophageal cancer	0.000201	0.00218	CcSEcCtD
Etodolac—Erythema multiforme—Methotrexate—esophageal cancer	0.000201	0.00217	CcSEcCtD
Etodolac—Shock—Capecitabine—esophageal cancer	0.000199	0.00216	CcSEcCtD
Etodolac—Thrombocytopenia—Capecitabine—esophageal cancer	0.000199	0.00215	CcSEcCtD
Etodolac—Tinnitus—Methotrexate—esophageal cancer	0.000198	0.00214	CcSEcCtD
Etodolac—Tachycardia—Capecitabine—esophageal cancer	0.000198	0.00214	CcSEcCtD
Etodolac—Asthenia—Cisplatin—esophageal cancer	0.000197	0.00214	CcSEcCtD
Etodolac—Hyperhidrosis—Capecitabine—esophageal cancer	0.000196	0.00212	CcSEcCtD
Etodolac—Anorexia—Capecitabine—esophageal cancer	0.000193	0.00209	CcSEcCtD
Etodolac—Chills—Methotrexate—esophageal cancer	0.000191	0.00206	CcSEcCtD
Etodolac—Hypotension—Capecitabine—esophageal cancer	0.000189	0.00205	CcSEcCtD
Etodolac—Diarrhoea—Cisplatin—esophageal cancer	0.000188	0.00204	CcSEcCtD
Etodolac—Alopecia—Methotrexate—esophageal cancer	0.000188	0.00203	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000185	0.002	CcSEcCtD
Etodolac—Insomnia—Capecitabine—esophageal cancer	0.000183	0.00198	CcSEcCtD
Etodolac—Paraesthesia—Capecitabine—esophageal cancer	0.000182	0.00197	CcSEcCtD
Etodolac—Dysgeusia—Methotrexate—esophageal cancer	0.000181	0.00196	CcSEcCtD
Etodolac—Dyspnoea—Capecitabine—esophageal cancer	0.000181	0.00196	CcSEcCtD
Etodolac—Dyspepsia—Capecitabine—esophageal cancer	0.000178	0.00193	CcSEcCtD
Etodolac—Decreased appetite—Capecitabine—esophageal cancer	0.000176	0.00191	CcSEcCtD
Etodolac—Vomiting—Cisplatin—esophageal cancer	0.000175	0.00189	CcSEcCtD
Etodolac—Fatigue—Capecitabine—esophageal cancer	0.000175	0.00189	CcSEcCtD
Etodolac—Vision blurred—Methotrexate—esophageal cancer	0.000174	0.00189	CcSEcCtD
Etodolac—Rash—Cisplatin—esophageal cancer	0.000173	0.00188	CcSEcCtD
Etodolac—Pain—Capecitabine—esophageal cancer	0.000173	0.00188	CcSEcCtD
Etodolac—Constipation—Capecitabine—esophageal cancer	0.000173	0.00188	CcSEcCtD
Etodolac—Dermatitis—Cisplatin—esophageal cancer	0.000173	0.00188	CcSEcCtD
Etodolac—Ill-defined disorder—Methotrexate—esophageal cancer	0.000172	0.00186	CcSEcCtD
Etodolac—Anaemia—Methotrexate—esophageal cancer	0.000171	0.00185	CcSEcCtD
Etodolac—Feeling abnormal—Capecitabine—esophageal cancer	0.000167	0.00181	CcSEcCtD
Etodolac—Malaise—Methotrexate—esophageal cancer	0.000167	0.0018	CcSEcCtD
Etodolac—Vertigo—Methotrexate—esophageal cancer	0.000166	0.0018	CcSEcCtD
Etodolac—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000166	0.00179	CcSEcCtD
Etodolac—Leukopenia—Methotrexate—esophageal cancer	0.000166	0.00179	CcSEcCtD
Etodolac—Nausea—Cisplatin—esophageal cancer	0.000163	0.00177	CcSEcCtD
Etodolac—Urticaria—Capecitabine—esophageal cancer	0.000161	0.00174	CcSEcCtD
Etodolac—Abdominal pain—Capecitabine—esophageal cancer	0.00016	0.00173	CcSEcCtD
Etodolac—Body temperature increased—Capecitabine—esophageal cancer	0.00016	0.00173	CcSEcCtD
Etodolac—Convulsion—Methotrexate—esophageal cancer	0.00016	0.00173	CcSEcCtD
Etodolac—Arthralgia—Methotrexate—esophageal cancer	0.000157	0.0017	CcSEcCtD
Etodolac—Myalgia—Methotrexate—esophageal cancer	0.000157	0.0017	CcSEcCtD
Etodolac—Discomfort—Methotrexate—esophageal cancer	0.000156	0.00168	CcSEcCtD
Etodolac—Confusional state—Methotrexate—esophageal cancer	0.000152	0.00165	CcSEcCtD
Etodolac—Anaphylactic shock—Methotrexate—esophageal cancer	0.000151	0.00163	CcSEcCtD
Etodolac—Infection—Methotrexate—esophageal cancer	0.00015	0.00162	CcSEcCtD
Etodolac—Hypersensitivity—Capecitabine—esophageal cancer	0.000149	0.00162	CcSEcCtD
Etodolac—Thrombocytopenia—Methotrexate—esophageal cancer	0.000148	0.0016	CcSEcCtD
Etodolac—Hyperhidrosis—Methotrexate—esophageal cancer	0.000146	0.00158	CcSEcCtD
Etodolac—Asthenia—Capecitabine—esophageal cancer	0.000145	0.00157	CcSEcCtD
Etodolac—Anorexia—Methotrexate—esophageal cancer	0.000144	0.00156	CcSEcCtD
Etodolac—Pruritus—Capecitabine—esophageal cancer	0.000143	0.00155	CcSEcCtD
Etodolac—Hypotension—Methotrexate—esophageal cancer	0.000141	0.00153	CcSEcCtD
Etodolac—Diarrhoea—Capecitabine—esophageal cancer	0.000139	0.0015	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000138	0.00149	CcSEcCtD
Etodolac—Insomnia—Methotrexate—esophageal cancer	0.000137	0.00148	CcSEcCtD
Etodolac—Paraesthesia—Methotrexate—esophageal cancer	0.000136	0.00147	CcSEcCtD
Etodolac—Dyspnoea—Methotrexate—esophageal cancer	0.000135	0.00146	CcSEcCtD
Etodolac—Somnolence—Methotrexate—esophageal cancer	0.000134	0.00145	CcSEcCtD
Etodolac—Dizziness—Capecitabine—esophageal cancer	0.000134	0.00145	CcSEcCtD
Etodolac—Dyspepsia—Methotrexate—esophageal cancer	0.000133	0.00144	CcSEcCtD
Etodolac—Decreased appetite—Methotrexate—esophageal cancer	0.000131	0.00142	CcSEcCtD
Etodolac—Fatigue—Methotrexate—esophageal cancer	0.00013	0.00141	CcSEcCtD
Etodolac—Pain—Methotrexate—esophageal cancer	0.000129	0.0014	CcSEcCtD
Etodolac—Vomiting—Capecitabine—esophageal cancer	0.000129	0.0014	CcSEcCtD
Etodolac—Rash—Capecitabine—esophageal cancer	0.000128	0.00138	CcSEcCtD
Etodolac—Dermatitis—Capecitabine—esophageal cancer	0.000128	0.00138	CcSEcCtD
Etodolac—Headache—Capecitabine—esophageal cancer	0.000127	0.00137	CcSEcCtD
Etodolac—Feeling abnormal—Methotrexate—esophageal cancer	0.000124	0.00135	CcSEcCtD
Etodolac—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000123	0.00134	CcSEcCtD
Etodolac—Nausea—Capecitabine—esophageal cancer	0.00012	0.0013	CcSEcCtD
Etodolac—Urticaria—Methotrexate—esophageal cancer	0.00012	0.0013	CcSEcCtD
Etodolac—Body temperature increased—Methotrexate—esophageal cancer	0.000119	0.00129	CcSEcCtD
Etodolac—Abdominal pain—Methotrexate—esophageal cancer	0.000119	0.00129	CcSEcCtD
Etodolac—Hypersensitivity—Methotrexate—esophageal cancer	0.000111	0.0012	CcSEcCtD
Etodolac—Asthenia—Methotrexate—esophageal cancer	0.000108	0.00117	CcSEcCtD
Etodolac—Pruritus—Methotrexate—esophageal cancer	0.000107	0.00116	CcSEcCtD
Etodolac—Diarrhoea—Methotrexate—esophageal cancer	0.000103	0.00112	CcSEcCtD
Etodolac—Dizziness—Methotrexate—esophageal cancer	9.98e-05	0.00108	CcSEcCtD
Etodolac—Vomiting—Methotrexate—esophageal cancer	9.6e-05	0.00104	CcSEcCtD
Etodolac—Rash—Methotrexate—esophageal cancer	9.52e-05	0.00103	CcSEcCtD
Etodolac—Dermatitis—Methotrexate—esophageal cancer	9.51e-05	0.00103	CcSEcCtD
Etodolac—Headache—Methotrexate—esophageal cancer	9.46e-05	0.00102	CcSEcCtD
Etodolac—Nausea—Methotrexate—esophageal cancer	8.97e-05	0.00097	CcSEcCtD
Etodolac—UGT2B7—Metabolism—PSME2—esophageal cancer	2.89e-05	0.000204	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PSME1—esophageal cancer	2.89e-05	0.000204	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	2.88e-05	0.000204	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CYP2A6—esophageal cancer	2.88e-05	0.000204	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP26A1—esophageal cancer	2.87e-05	0.000203	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.87e-05	0.000203	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.87e-05	0.000203	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GNG7—esophageal cancer	2.85e-05	0.000201	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ALOX15—esophageal cancer	2.8e-05	0.000198	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.8e-05	0.000198	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ADH7—esophageal cancer	2.8e-05	0.000198	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PLCE1—esophageal cancer	2.8e-05	0.000198	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	2.78e-05	0.000196	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.77e-05	0.000196	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.76e-05	0.000195	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CYP19A1—esophageal cancer	2.75e-05	0.000195	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ENO1—esophageal cancer	2.73e-05	0.000193	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTGS1—esophageal cancer	2.73e-05	0.000193	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.73e-05	0.000193	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PSME2—esophageal cancer	2.69e-05	0.00019	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PSME1—esophageal cancer	2.69e-05	0.00019	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—ERBB2—esophageal cancer	2.69e-05	0.00019	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—TPI1—esophageal cancer	2.67e-05	0.000189	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTO1—esophageal cancer	2.67e-05	0.000189	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ALDH2—esophageal cancer	2.67e-05	0.000189	CbGpPWpGaD
Etodolac—ALB—Metabolism—CA1—esophageal cancer	2.66e-05	0.000188	CbGpPWpGaD
Etodolac—ALB—Metabolism—SLC10A2—esophageal cancer	2.66e-05	0.000188	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.64e-05	0.000187	CbGpPWpGaD
Etodolac—PTGS2—Disease—ELMO1—esophageal cancer	2.59e-05	0.000183	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC52A3—esophageal cancer	2.56e-05	0.000181	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—BLVRB—esophageal cancer	2.56e-05	0.000181	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ALDOB—esophageal cancer	2.56e-05	0.000181	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTT1—esophageal cancer	2.54e-05	0.00018	CbGpPWpGaD
Etodolac—PTGS2—Disease—GSTO1—esophageal cancer	2.53e-05	0.000179	CbGpPWpGaD
Etodolac—PTGS2—Disease—TPI1—esophageal cancer	2.53e-05	0.000179	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—HMOX1—esophageal cancer	2.51e-05	0.000178	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYP2A6—esophageal cancer	2.51e-05	0.000177	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.5e-05	0.000177	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CYP1B1—esophageal cancer	2.49e-05	0.000176	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GAPDH—esophageal cancer	2.46e-05	0.000174	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—SMAD4—esophageal cancer	2.46e-05	0.000174	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ADH1B—esophageal cancer	2.45e-05	0.000173	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CRABP1—esophageal cancer	2.44e-05	0.000173	CbGpPWpGaD
Etodolac—ALB—Metabolism—CA2—esophageal cancer	2.43e-05	0.000172	CbGpPWpGaD
Etodolac—PTGS2—Disease—ALDOB—esophageal cancer	2.43e-05	0.000172	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ABCB1—esophageal cancer	2.41e-05	0.00017	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.39e-05	0.000169	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ENO1—esophageal cancer	2.38e-05	0.000168	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTGS1—esophageal cancer	2.38e-05	0.000168	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.38e-05	0.000168	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.35e-05	0.000166	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PSME2—esophageal cancer	2.34e-05	0.000166	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PSME1—esophageal cancer	2.34e-05	0.000166	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TYMP—esophageal cancer	2.34e-05	0.000166	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CYP19A1—esophageal cancer	2.34e-05	0.000166	CbGpPWpGaD
Etodolac—PTGS2—Disease—HIST1H2BM—esophageal cancer	2.34e-05	0.000165	CbGpPWpGaD
Etodolac—PTGS2—Disease—GAPDH—esophageal cancer	2.34e-05	0.000165	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GNG7—esophageal cancer	2.32e-05	0.000164	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CYP1B1—esophageal cancer	2.32e-05	0.000164	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.3e-05	0.000163	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.29e-05	0.000162	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP26A1—esophageal cancer	2.28e-05	0.000161	CbGpPWpGaD
Etodolac—ALB—Metabolism—PLCE1—esophageal cancer	2.26e-05	0.00016	CbGpPWpGaD
Etodolac—ALB—Metabolism—ADH7—esophageal cancer	2.26e-05	0.00016	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.25e-05	0.000159	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.24e-05	0.000158	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ALOX15—esophageal cancer	2.22e-05	0.000157	CbGpPWpGaD
Etodolac—ALB—Hemostasis—ABL1—esophageal cancer	2.22e-05	0.000157	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EP300—esophageal cancer	2.19e-05	0.000155	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CYP19A1—esophageal cancer	2.18e-05	0.000154	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—SLC10A2—esophageal cancer	2.18e-05	0.000154	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CA1—esophageal cancer	2.18e-05	0.000154	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ALDH2—esophageal cancer	2.18e-05	0.000154	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—HMOX1—esophageal cancer	2.14e-05	0.000151	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—TPI1—esophageal cancer	2.12e-05	0.00015	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTO1—esophageal cancer	2.12e-05	0.00015	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTT1—esophageal cancer	2.07e-05	0.000146	CbGpPWpGaD
Etodolac—PTGS2—Disease—XIAP—esophageal cancer	2.06e-05	0.000146	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ABCB1—esophageal cancer	2.05e-05	0.000145	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.05e-05	0.000145	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP2A6—esophageal cancer	2.05e-05	0.000145	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.04e-05	0.000144	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ALDOB—esophageal cancer	2.03e-05	0.000144	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—MYC—esophageal cancer	2.03e-05	0.000143	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYP1B1—esophageal cancer	2.02e-05	0.000143	CbGpPWpGaD
Etodolac—RXRA—Metabolism—HMOX1—esophageal cancer	1.99e-05	0.000141	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CA2—esophageal cancer	1.99e-05	0.000141	CbGpPWpGaD
Etodolac—ALB—Metabolism—ADH1B—esophageal cancer	1.98e-05	0.00014	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GAPDH—esophageal cancer	1.96e-05	0.000138	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.95e-05	0.000138	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.95e-05	0.000138	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.95e-05	0.000138	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.94e-05	0.000137	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ENO1—esophageal cancer	1.94e-05	0.000137	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CRABP1—esophageal cancer	1.94e-05	0.000137	CbGpPWpGaD
Etodolac—PTGS2—Disease—B2M—esophageal cancer	1.92e-05	0.000136	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ABCB1—esophageal cancer	1.91e-05	0.000135	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PSME2—esophageal cancer	1.91e-05	0.000135	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PSME1—esophageal cancer	1.91e-05	0.000135	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYP19A1—esophageal cancer	1.9e-05	0.000134	CbGpPWpGaD
Etodolac—ALB—Metabolism—TYMP—esophageal cancer	1.9e-05	0.000134	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.89e-05	0.000134	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EGFR—esophageal cancer	1.87e-05	0.000132	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.86e-05	0.000132	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PLCE1—esophageal cancer	1.85e-05	0.000131	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ADH7—esophageal cancer	1.85e-05	0.000131	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP26A1—esophageal cancer	1.84e-05	0.00013	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GNG7—esophageal cancer	1.84e-05	0.00013	CbGpPWpGaD
Etodolac—PTGS2—Disease—ENO1—esophageal cancer	1.84e-05	0.00013	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.83e-05	0.000129	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—NOTCH1—esophageal cancer	1.81e-05	0.000128	CbGpPWpGaD
Etodolac—PTGS2—Disease—PSME2—esophageal cancer	1.81e-05	0.000128	CbGpPWpGaD
Etodolac—PTGS2—Disease—PSME1—esophageal cancer	1.81e-05	0.000128	CbGpPWpGaD
Etodolac—ALB—Metabolism—ALOX15—esophageal cancer	1.8e-05	0.000127	CbGpPWpGaD
Etodolac—PTGS2—Disease—CALR—esophageal cancer	1.74e-05	0.000123	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—HMOX1—esophageal cancer	1.74e-05	0.000123	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ALDH2—esophageal cancer	1.73e-05	0.000122	CbGpPWpGaD
Etodolac—ALB—Metabolism—TPI1—esophageal cancer	1.71e-05	0.000121	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTO1—esophageal cancer	1.71e-05	0.000121	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.7e-05	0.00012	CbGpPWpGaD
Etodolac—PTGS2—Disease—FBXW7—esophageal cancer	1.68e-05	0.000119	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.67e-05	0.000118	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ABCB1—esophageal cancer	1.67e-05	0.000118	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP1B1—esophageal cancer	1.65e-05	0.000117	CbGpPWpGaD
Etodolac—ALB—Metabolism—ALDOB—esophageal cancer	1.64e-05	0.000116	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—CREBBP—esophageal cancer	1.64e-05	0.000116	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTT1—esophageal cancer	1.64e-05	0.000116	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP2A6—esophageal cancer	1.62e-05	0.000115	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.62e-05	0.000115	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.62e-05	0.000114	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CREBBP—esophageal cancer	1.61e-05	0.000114	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NOS2—esophageal cancer	1.6e-05	0.000113	CbGpPWpGaD
Etodolac—ALB—Metabolism—GAPDH—esophageal cancer	1.58e-05	0.000112	CbGpPWpGaD
Etodolac—ALB—Metabolism—CRABP1—esophageal cancer	1.57e-05	0.000111	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TYMP—esophageal cancer	1.55e-05	0.00011	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP19A1—esophageal cancer	1.55e-05	0.00011	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ENO1—esophageal cancer	1.54e-05	0.000109	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PTGS1—esophageal cancer	1.54e-05	0.000109	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PSME2—esophageal cancer	1.52e-05	0.000107	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PSME1—esophageal cancer	1.52e-05	0.000107	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.51e-05	0.000107	CbGpPWpGaD
Etodolac—ALB—Metabolism—GNG7—esophageal cancer	1.49e-05	0.000105	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.47e-05	0.000104	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.45e-05	0.000102	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—NOS3—esophageal cancer	1.44e-05	0.000102	CbGpPWpGaD
Etodolac—ALB—Hemostasis—CREBBP—esophageal cancer	1.44e-05	0.000102	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—HMOX1—esophageal cancer	1.41e-05	0.0001	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.41e-05	9.94e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—TPI1—esophageal cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—ALDH2—esophageal cancer	1.4e-05	9.88e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.39e-05	9.81e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CREBBP—esophageal cancer	1.37e-05	9.69e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—TGFBR2—esophageal cancer	1.36e-05	9.62e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ABCB1—esophageal cancer	1.36e-05	9.6e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.35e-05	9.51e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTT1—esophageal cancer	1.33e-05	9.4e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTGS2—esophageal cancer	1.32e-05	9.33e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP2A6—esophageal cancer	1.31e-05	9.29e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP1B1—esophageal cancer	1.31e-05	9.26e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.31e-05	9.26e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.3e-05	9.16e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—SMAD4—esophageal cancer	1.29e-05	9.1e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NOS3—esophageal cancer	1.29e-05	9.1e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.28e-05	9.08e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CREBBP—esophageal cancer	1.28e-05	9.04e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.26e-05	8.91e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—ENO1—esophageal cancer	1.25e-05	8.81e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTGS1—esophageal cancer	1.25e-05	8.81e-05	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.24e-05	8.8e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.23e-05	8.7e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PSME2—esophageal cancer	1.23e-05	8.68e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PSME1—esophageal cancer	1.23e-05	8.68e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—NOS3—esophageal cancer	1.23e-05	8.67e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GNG7—esophageal cancer	1.22e-05	8.63e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—NOS3—esophageal cancer	1.14e-05	8.09e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.14e-05	8.09e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—HMOX1—esophageal cancer	1.12e-05	7.94e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTGS2—esophageal cancer	1.12e-05	7.93e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CREBBP—esophageal cancer	1.11e-05	7.87e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.1e-05	7.79e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—EP300—esophageal cancer	1.1e-05	7.76e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.09e-05	7.69e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ABCB1—esophageal cancer	1.08e-05	7.62e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.08e-05	7.61e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.07e-05	7.58e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.07e-05	7.58e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP1B1—esophageal cancer	1.06e-05	7.49e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—HIF1A—esophageal cancer	1.05e-05	7.45e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTGS2—esophageal cancer	1.05e-05	7.4e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.03e-05	7.26e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ENO1—esophageal cancer	1.02e-05	7.21e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.02e-05	7.21e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PSME1—esophageal cancer	1e-05	7.1e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PSME2—esophageal cancer	1e-05	7.1e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—NOS3—esophageal cancer	9.97e-06	7.05e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP19A1—esophageal cancer	9.96e-06	7.04e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—EP300—esophageal cancer	9.79e-06	6.92e-05	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—MYC—esophageal cancer	9.76e-06	6.9e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—NOS2—esophageal cancer	9.58e-06	6.78e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—NOTCH1—esophageal cancer	9.49e-06	6.71e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—EP300—esophageal cancer	9.33e-06	6.6e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTGS2—esophageal cancer	9.12e-06	6.45e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—HMOX1—esophageal cancer	9.09e-06	6.43e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CREBBP—esophageal cancer	9.08e-06	6.42e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.92e-06	6.3e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.77e-06	6.2e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—ABCB1—esophageal cancer	8.72e-06	6.17e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—EP300—esophageal cancer	8.7e-06	6.16e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP1B1—esophageal cancer	8.67e-06	6.13e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CREBBP—esophageal cancer	8.6e-06	6.08e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP19A1—esophageal cancer	8.15e-06	5.76e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.15e-06	5.76e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—NOS3—esophageal cancer	8.13e-06	5.75e-05	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PIK3CA—esophageal cancer	8.12e-06	5.74e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—NOS3—esophageal cancer	7.7e-06	5.45e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—EP300—esophageal cancer	7.58e-06	5.36e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—HMOX1—esophageal cancer	7.44e-06	5.26e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTGS2—esophageal cancer	7.43e-06	5.26e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.3e-06	5.16e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PIK3CA—esophageal cancer	7.24e-06	5.12e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CREBBP—esophageal cancer	7.21e-06	5.09e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—ERBB2—esophageal cancer	7.21e-06	5.09e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ABCB1—esophageal cancer	7.14e-06	5.05e-05	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—esophageal cancer	7.01e-06	4.96e-05	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PIK3CA—esophageal cancer	6.9e-06	4.88e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.59e-06	4.66e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NOS3—esophageal cancer	6.45e-06	4.56e-05	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PIK3CA—esophageal cancer	6.44e-06	4.55e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—EP300—esophageal cancer	6.18e-06	4.37e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—CDKN1A—esophageal cancer	6.16e-06	4.35e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—EP300—esophageal cancer	5.86e-06	4.14e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—CREBBP—esophageal cancer	5.83e-06	4.12e-05	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PIK3CA—esophageal cancer	5.61e-06	3.97e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.4e-06	3.82e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—NOS3—esophageal cancer	5.22e-06	3.69e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—MYC—esophageal cancer	5.11e-06	3.61e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—EGFR—esophageal cancer	4.99e-06	3.53e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—EP300—esophageal cancer	4.91e-06	3.47e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTGS2—esophageal cancer	4.77e-06	3.38e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.77e-06	3.37e-05	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PIK3CA—esophageal cancer	4.57e-06	3.23e-05	CbGpPWpGaD
Etodolac—PTGS2—Disease—PIK3CA—esophageal cancer	4.33e-06	3.07e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NOS3—esophageal cancer	4.27e-06	3.02e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—EP300—esophageal cancer	3.97e-06	2.81e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.91e-06	2.76e-05	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PIK3CA—esophageal cancer	3.63e-06	2.57e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—EP300—esophageal cancer	3.25e-06	2.3e-05	CbGpPWpGaD
Etodolac—ALB—Metabolism—PIK3CA—esophageal cancer	2.94e-06	2.08e-05	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.4e-06	1.7e-05	CbGpPWpGaD
